Next Article in Journal
PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis
Next Article in Special Issue
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Previous Article in Journal
Twisted Intramolecular Charge Transfer State of a “Push-Pull” Emitter
Previous Article in Special Issue
Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia
Review

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches

1
Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea
2
Center for Genome Engineering, Institute for Basic Science (IBS), 55 Expo-ro, Yuseong-gu, Daejeon 34126, Korea
3
Environmental Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Yuseong-gu, Daejeon 34141, Korea
4
Department of Functional Genomics, Korea University of Science and Technology (UST), 113 Gwahak-ro, Yuseong-gu, Daejeon 34113, Korea
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(21), 8000; https://doi.org/10.3390/ijms21218000
Received: 28 September 2020 / Revised: 21 October 2020 / Accepted: 26 October 2020 / Published: 27 October 2020
(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
Immunotherapy is extensively investigated for almost all types of hematologic tumors, from preleukemic to relapse/refractory malignancies. Due to the emergence of technologies for target cell characterization, antibody design and manufacturing, as well as genome editing, immunotherapies including gene and cell therapies are becoming increasingly elaborate and diversified. Understanding the tumor immune microenvironment of the target disease is critical, as is reducing toxicity. Although there have been many successes and newly FDA-approved immunotherapies for hematologic malignancies, we have learned that insufficient efficacy due to disease relapse following treatment is one of the key obstacles for developing successful therapeutic regimens. Thus, combination therapies are also being explored. In this review, immunotherapies for each type of hematologic malignancy will be introduced, and novel targets that are under investigation will be described. View Full-Text
Keywords: hematologic malignancy; immune checkpoint; chimeric antigen receptor; lymphocyte; antibody–drug conjugate hematologic malignancy; immune checkpoint; chimeric antigen receptor; lymphocyte; antibody–drug conjugate
Show Figures

Figure 1

MDPI and ACS Style

Noh, J.-Y.; Seo, H.; Lee, J.; Jung, H. Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. Int. J. Mol. Sci. 2020, 21, 8000. https://doi.org/10.3390/ijms21218000

AMA Style

Noh J-Y, Seo H, Lee J, Jung H. Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. International Journal of Molecular Sciences. 2020; 21(21):8000. https://doi.org/10.3390/ijms21218000

Chicago/Turabian Style

Noh, Ji-Yoon, Huiyun Seo, Jungwoon Lee, and Haiyoung Jung. 2020. "Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches" International Journal of Molecular Sciences 21, no. 21: 8000. https://doi.org/10.3390/ijms21218000

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop